Hijama bil shart (Wet cupping) in the management of sciatic pain

Clinical validation and development of SOPs of Hijama bil shart (Wet cupping) in the management of Irq-al-Nasa (sciatic pain)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/03/012734

Enrollment

Registered

2018-03-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- sciatic pain

Interventions

Intervention1: Hijama bil Shart (Wet Cupping i.e. therapy) once a week AND Habb e Suranjan two tablets orally was given twice a day for a period of four weeks.: Procedure of Hijama bil Shart (Wet Cu

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either sex between the age of 18 and 65 years. 2. Already diagnosed patients of sciatica presenting with all or some of the following signs and symptoms Unilateral leg pain greater than low back pain Pain radiating to foot or toes Numbness and or paraesthesia in the same distribution Tingling , pins and needles Muscle weakness

Exclusion criteria

Exclusion criteria: 1.Patients below 18 years and above 65 years of age 2.Pregnant and lactating females 3.Patients of previous back surgery/lumbar spine surgery 4.Patients of spinal tumors and vertebral fracture 5.Patients of developmental spine deformities 6.Patients of bleeding disorders 7.Patients on anticoagulant treatment/ disseminated intravascular coagulation 8.Patients taking any other conservative treatment for sciatica (NSAIDS, corticosteroids, acupuncture etc.) 9.Patients with systemic disorders like chronic liver, kidney or heart disease 10.Patients of uncontrolled diabetes mellitus 11.Terminally ill patients

Design outcomes

Primary

Measure	Time frame
1.Sign and symptoms- Unilateral leg pain greater than low back pain Pain radiating to foot or toes Numbness and paraesthesia in the same distribution Tingling , pins and needles Muscle weakness 2.VAS (Visual Analogue Scale for leg pain) 3.The Sciatica Bothersomeness Index (SBI) 4.The Maine-Seattle Back questionnaire (MSBQ) 5. SF12v2 generic quality of life questionnaire Timepoint: pre and post treatment ( day 0 and day 28th)	—

Measure

Time frame

1.Sign and symptoms- Unilateral leg pain greater than low back pain Pain radiating to foot or toes Numbness and paraesthesia in the same distribution Tingling , pins and needles Muscle weakness 2.VAS (Visual Analogue Scale for leg pain) 3.The Sciatica Bothersomeness Index (SBI) 4.The Maine-Seattle Back questionnaire (MSBQ) 5. SF12v2 generic quality of life questionnaire Timepoint: pre and post treatment ( day 0 and day 28th)

—

Secondary

Measure	Time frame
Radiological parameter (X-Ray Lumbosacral Spine AP and lateral views)Timepoint: pre treatment and post treatment ( day 0 and day 28)	—

Countries

India

Contacts

Public ContactDr Shazia Jilani

Jamia Hamdard

syedshakirjamil@rediffmail.com9873112115

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026